Jérôme Hadjadj,Nader Yatim,Laura Barnabei,Aurélien Corneau,Jeremy Boussier,Nikaïa Smith,Hélène Péré,Bruno Charbit,Vincent Bondet,Camille Chenevier-Gobeaux,Paul Breillat,Nicolas Carlier,Rémy Gauzit,Caroline Morbieu,Frédéric Pène,Nathalie Marin,Nicolas Roche,Tali-Anne Szwebel,Sarah H Merkling,Jean-Marc Treluyer,David Veyer,Luc Mouthon,Catherine Blanc,Pierre-Louis Tharaux,Flore Rozenberg,Alain Fischer,Darragh Duffy,Frédéric Rieux-Laucat,Solen Kernéis,Benjamin Terrier,Sarah H. Merkling

Abstract:Interferons interfere with lung repair Interferons (IFNs) are central to antiviral immunity. Viral recognition elicits IFN production, which in turn triggers the transcription of IFN-stimulated genes (ISGs), which engage in various antiviral functions. Type I IFNs (IFN-α and IFN-β) are widely expressed and can result in immunopathology during viral infections. By contrast, type III IFN (IFN-λ) responses are primarily restricted to mucosal surfaces and are thought to confer antiviral protection without driving damaging proinflammatory responses. Accordingly, IFN-λ has been proposed as a therapeutic in coronavirus disease 2019 (COVID-19) and other such viral respiratory diseases (see the Perspective by Grajales-Reyes and Colonna). Broggi et al. report that COVID-19 patient morbidity correlates with the high expression of type I and III IFNs in the lung. Furthermore, IFN-λ secreted by dendritic cells in the lungs of mice exposed to synthetic viral RNA causes damage to the lung epithelium, which increases susceptibility to lethal bacterial superinfections. Similarly, using a mouse model of influenza infection, Major et al. found that IFN signaling (especially IFN-λ) hampers lung repair by inducing p53 and inhibiting epithelial proliferation and differentiation. Complicating this picture, Hadjadj et al. observed that peripheral blood immune cells from severe and critical COVID-19 patients have diminished type I IFN and enhanced proinflammatory interleukin-6– and tumor necrosis factor-α–fueled responses. This suggests that in contrast to local production, systemic production of IFNs may be beneficial. The results of this trio of studies suggest that the location, timing, and duration of IFN exposure are critical parameters underlying the success or failure of therapeutics for viral respiratory infections. Science , this issue p. 706 , p. 712 , p. 718 ; see also p. 626

The Timing and Magnitude of the Type I Interferon Response Are Correlated with Disease Tolerance in Arbovirus Infection

Relative Timing of Type I Interferon Response and Virus Replication Determines Disease Outcome During Respiratory Virus Infection

Single Cell Transcriptomic Dissection of Virus Induced Immunopathology in Interferon Gamma Receptor Null Mice

Type I interferons in infectious disease

A Commentary of “type I Interferon Deficiency Can Lead to Severe COVID-19” in 10 Remarkable Discoveries from 2020 in Nature

Type I Interferon Responses by HIV-1 Infection: Association with Disease Progression and Control

Interferons: signaling, antiviral and viral evasion

Protective versus Pathogenic Type I Interferon Responses during Virus Infections

The Roles of Type I Interferon in Co-infections with Parasites and Viruses, Bacteria, or Other Parasites.

Human Type I Interferon Antiviral Effects in Respiratory and Reemerging Viral Infections

IFN-I Response Timing Relative to Virus Replication Determines MERS Coronavirus Infection Outcomes

The Interplay Between Coronavirus and Type I IFN Response

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Type I Interferon-Mediated Regulation of Antiviral Capabilities of Neutrophils

Type I Interferons And Malaria: A Double-Edge Sword Against A Complex Parasitic Disease

Spatiotemporal regulation of type I interferon expression determines the antiviral polarization of CD4+ T cells

The Dual Nature of Type I and Type II Interferons

Viral infections in humans and mice with genetic deficiencies of the type I IFN response pathway

Type I interferon signaling attenuates regulatory T cell function in viral infection and in the tumor microenvironment

Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency

Role of Type I Interferons during Mycobacterium tuberculosis and HIV Infections